Relatlimab
Highest phase reached
Approved
Drug type
Antibody
First approval year
2022
- First approval year
- 2022
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Antibody
- Drug name
- Relatlimab
- relatlimab component of bms 986213
- Relatlimab component of bms-986213
- Relatlimab component of opdualag -rmbw
- relatlimab component of opdualag rmbw
- bms 986016
- bms 986213 component relatlimab
- BMS-986016
- BMS-986213 COMPONENT RELATLIMAB
- opdualag component relatlimab rmbw
- OPDUALAG COMPONENT RELATLIMAB-RMBW
- relatlimab
- Relatlimab
- relatlimab [INN]
- Relatlimab [MI]
- RELATLIMAB [USAN]
- Relatlimab [WHO-DD]
- relatlimab inn
- relatlimab mi
- relatlimab rmbw
- Relatlimab rmbw
- Relatlimab rmbw [WHO-DD]
- relatlimab rmbw who dd
- relatlimab usan
- relatlimab who dd
- Relatlimab-rmbw
- CAS registry numbers
- 1673516-98-7
- ChEMBL ID
- CHEMBL3990044
- FDA ingredient codes (UNII)
- AF75XOF6W3
- 2596772
- 2596773
- Applicant
- BRISTOL MYERS SQUIBB
- Approval date
- 18 Mar 2022
- Application number
- BLA761234
- First in class
- Yes
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- relatlimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- LAG3 (CD223)
- Gene symbol
- LAG3
- Protein identifier
- P18627
- Primary target
- Yes
- Mechanism
- Lymphocyte activation gene 3 protein inhibitor
- Action type
- Inhibitor
- Target
- Lymphocyte activation gene 3 protein
- Protein identifier
- P18627
Open Targets mechanisms
- Mechanism
- Lymphocyte activation gene 3 protein inhibitor
- Action type
- Inhibitor
- Target
- Lymphocyte activation gene 3 protein
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Glioblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002617
- Subject identifier
- D008545
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Carcinoma, Basal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004193
- Subject identifier
- D002280
- Condition
- Uveal Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000616
- Subject identifier
- D000098943
- Condition
- Gliosarcoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001465
- Subject identifier
- D018316
- Condition
- Carcinoma, Merkel Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001471
- Subject identifier
- D015266
- Condition
- Colonic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001950
- Subject identifier
- D003110
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001951
- Subject identifier
- D015179
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001968
- Subject identifier
- D012509
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Liver Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002691
- Subject identifier
- D008113
And 6 more, listed on the interactive page.
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000389
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000756
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002617
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004193
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001471
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001927
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000544
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001325
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001402
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001528
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002271
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004952
- Highest recorded phase
- 1
And 34 more, listed on the interactive page.
- Event
- adrenal insufficiency
- Reports
- 4
- Reporting signal score
- 11.5086
- Event
- hepatitis
- Reports
- 5
- Reporting signal score
- 10.822
- Event
- meningitis aseptic
- Reports
- 4
- Reporting signal score
- 14.8673
- Event
- pericardial effusion
- Reports
- 5
- Reporting signal score
- 12.3489
- NCT01968109
- NCT03607890
- NCT05400265
- NCT05498480
- NCT02060188
- NCT02061761
- NCT02488759
- NCT02750514
- NCT02966548
- NCT02996110
- NCT03335540
- NCT03459222
- NCT03899155
- NCT04112498
- NCT02658981
- NCT02935634
- NCT03704077
- NCT03026140
- NCT03310619
- NCT03470922
- NCT03743766
- NCT03978611
- NCT05002569
- NCT05418972
- NCT05428007
And 35 more, listed on the interactive page.
- Dose
- 160 mg relatlimab
- Route
- Intravenous
- How often
- Every 4 weeks
Conditions of use
- Administer as an intravenous infusion over 30 minutes
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- Q1VQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
- Component
- Light chain
- Type
- Protein
- Sequence
- EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges location
- Sequence
- 22-95$22''-95''$23'-88'$23'''-88'''$134'-194'$134'''-194'''$134-214'$134''-214'''$147-203$147''-203''$226-226''$229-229''$261-321$261''-321''$367-425$367''-425''
- 0003-7125
Related records
Trials (88)
- A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
- A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
- A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
- A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
- A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
- A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
- A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
- A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
- A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
- A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
In development for (31)
- Acute myeloid leukemia Phase 2
- Basal cell carcinoma Phase 2
- Cancer Phase 2
- Chordoma Phase 2
- Colon carcinoma Phase 2
- Colorectal adenocarcinoma Phase 3
- Colorectal carcinoma Phase 3
- Colorectal neoplasm Phase 3
- Cutaneous melanoma Phase 3
- Cutaneous neuroendocrine carcinoma Phase 2
- Diffuse large B-cell lymphoma Phase 1
- Esophageal cancer Phase 1
- Follicular lymphoma Phase 1
- Gastric cancer Phase 2
- Glioblastoma Phase 1
- Gliosarcoma Phase 1
- Head and neck squamous cell carcinoma Phase 2
- Hematopoietic and lymphoid cell neoplasm Phase 1
- Hepatocellular carcinoma Phase 2
- Liver cancer Phase 2
Targets (1)
- LAG3 Lymphocyte activation gene 3 protein inhibitor